ROIV insider buying – Roivant Sciences Ltd.
3 insider purchases since 2016 worth $20.2M by 3 different insiders. Last 12 months: 0 purchases, $0. Most recent filing: 2025-09-18.
Large company Public float $9.8B (latest 10-K, SEC).
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| Oren Dan 10% Owner | $20.0M 1× · 4,000,000 sh | 2022-11-10 2022-11-10 | – | 102,849,443 shares as of 2022-11-14 | Holds - never sold |
| Dexcel Pharma Technologies Ltd. 10% Owner | $154,980 1× · 40,285 sh | 2022-04-22 2022-04-22 | – | 98,849,443 shares as of 2022-04-26 | Holds - never sold |
| Gline Matthew CEO | $49,957 1× · 3,315 sh | 2025-09-18 2025-09-18 | 13× · $71.7M last 2026-04-16 | 16,659,945 shares as of 2026-07-02 | Sold part |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 0 | – | – | 27 | $382.4M |
| 2025 | 1 | $49,957 | 1 | 30 | $403.0M |
| 2024 | 0 | – | – | 13 | $152.4M |
| 2023 | 0 | – | – | 27 | $754.4M |
| 2022 | 2 | $20.2M | 2 | 22 | $70.7M |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2025-09-18 | Gline Matthew | CEO | 3,315 | $15.07 | $49,957 | +0.0% | SEC |
| 2022-11-14 | Oren Dan | 10% Owner | 4,000,000 | $5.00 | $20.0M | +4.0% | SEC |
| 2022-04-26 | Dexcel Pharma Technologies Ltd. | 10% Owner | 40,285 | $3.85 | $154,980 | +0.0% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-11-12 | Pulik Richard | CFO | -300,000 | $41.58 | $12.5M | Sale | SEC |
| 2026-11-12 | Venker Eric | President & Immunovant CEO | -187,943 | $40.53 | $7.6M | Pre-planned (10b5-1) | SEC |
| 2026-09-17 | Fitzgerald Meghan | Director | 5,112 | $39.74 | $203,152 | Pre-planned (10b5-1) | SEC |
| 2026-09-17 | Epperly Melissa B, | Director | 4,938 | $39.74 | $196,230 | Pre-planned (10b5-1) | SEC |
| 2026-09-10 | Fitzgerald Meghan | Director | 20,000 | $39.90 | $798,000 | Sale | SEC |
| 2026-09-01 | Venker Eric | CEO | 200,000 | $35.77 | $7.2M | Sale | SEC |
| 2026-08-21 | Sukhatme Mayukh | CEO | 335,174 | $36.88 | $12.4M | Sale | SEC |
| 2026-08-18 | Sukhatme Mayukh | CEO | 664,826 | $36.34 | $24.2M | Sale | SEC |
| 2026-07-29 | Venker Eric | CEO | 200,000 | $34.95 | $7.0M | Sale | SEC |
| 2026-07-02 | Fitzgerald Meghan | Director | 10,000 | $34.90 | $349,000 | Pre-planned (10b5-1) | SEC |
| 2026-07-01 | Epperly Melissa B, | Director | 17,750 | $34.38 | $610,252 | Pre-planned (10b5-1) | SEC |
| 2026-06-30 | QVT Financial LP | Other | 1,438,163 | $34.32 | $49.4M | Sale | SEC |
| 2026-06-30 | MANCHESTER KEITH S | Director | 1,638,163 | $34.46 | $56.4M | Sale | SEC |
| 2026-06-29 | Sukhatme Mayukh | CEO | 1,000,000 | $34.10 | $34.1M | Sale | SEC |
| 2026-06-26 | Venker Eric | CEO | 200,000 | $33.16 | $6.6M | Pre-planned (10b5-1) | SEC |
Showing the latest 15 of 119 sales of $50,000+ since 2016.
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free